Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MPW stock price vs WELL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WELL's multiple
Needs WELL P/S.
Implied fair value · at MPW's multiple
Needs MPW P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MEDICAL PROPERTIES TRUST INC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
WELLTOWER INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Sabra Health Care REIT, Inc.
MPW vs SBRA
Ventas, Inc.
MPW vs VTR
NATIONAL HEALTH INVESTORS INC
MPW vs NHI
OMEGA HEALTHCARE INVESTORS INC
MPW vs OHI
LTC PROPERTIES INC
MPW vs LTC
COSTAR GROUP, INC.
MPW vs CSGP
Prologis, Inc.
MPW vs PLD
Public Storage
MPW vs PSA
EQUITY RESIDENTIAL
MPW vs EQR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MPW's large negative earnings are temporary and the company can normalize profitability to WELL-like margins (allowing P/S or EV/Revenue re-rating), then consider a speculative buy because WELL-implied valuation ($25.06) far exceeds the current price ($5.11); otherwise, avoid or wait for operational improvement given MPW's negative net income (-$2.4B), negative EBITDA margin (-195.7%), and low Piotroski score (3/9).
There is a large pricing gap versus WELL-implied price: WELL-implied valuation implies $25.06 while MPW trades at $5.11. The gap is driven by much higher WELL multiples (WELL P/S 15.1x) and MPW's depressed market metrics despite MPW sitting near the middle of its historical band.
Supporting Metrics
